Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer&#039;s disease in the context of a structured 5-phase development framework

Chiotis, Konstantinos; Saint-Aubert, Laure; Boccardi, Marina; Gietl, Anton; Picco, Agnese; Varrone, Andrea; Garibotto, Valentina; Herholz, Karl; Nobili, Flavio; Nordberg, Agneta

doi:10.1016/j.neurobiolaging.2016.07.012

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Authors		Chiotis, Konstantinos Saint-Aubert, Laure Boccardi, Marina Gietl, Anton Picco, Agnese Varrone, Andrea Garibotto, Valentina Herholz, Karl Nobili, Flavio Nordberg, Agneta show all authors [1 - 10]
Published in		Neurobiology of Aging. 2017, vol. 52, p. 214-227
Abstract		The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. The aims of phase 3 (early detection ability) have been partly achieved, while phase 4 studies (performance in representative mild cognitive impairment patients) are currently ongoing. Phase 5 studies (quantification of impact and costs) are still to come. This review highlights the priorities to be pursued to enable the proper use of amyloid PET imaging in a clinical setting. Future investigations will primarily be large, phase 4 studies that will assess the utility of amyloid PET imaging in routine clinical practice.
Identifiers		DOI: 10.1016/j.neurobiolaging.2016.07.012 PMID: 28317650
Full text		Article (Published version) (1 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de psychiatrie Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale
Research groups		Laboratoire de neuroimagerie et de traceurs moléculaires innovants (984) Troubles de mémoire et maladie d'Alzeimer (935)
Citation (ISO format)		CHIOTIS, Konstantinos et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. In: Neurobiology of Aging, 2017, vol. 52, p. 214-227. doi: 10.1016/j.neurobiolaging.2016.07.012 https://archive-ouverte.unige.ch/unige:94309